15 Stocks That Will Go to The Moon According to Analysts

Page 4 of 14

11. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Average Upside Potential: 42.79%

Number of Hedge Fund Holders: 68

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company developing and commercializing life-transforming medicines for those having serious diseases. The firm’s medicines and pipeline are made for patients with eye diseases, cancer, cardiovascular and metabolic diseases, allergic and inflammatory diseases, hematologic conditions, neurological diseases, infectious diseases, and rare diseases.

With over 35 years of scientific leadership, 13 approved or authorized medicines, nearly 100% of drug candidates invested and developed in-house, and nearly 40 product candidates in clinical development across various therapeutic areas, Regeneron has a solid history in its industry to offer at a glance. Simultaneously, Regeneron Genetics Center has crafted the biggest DNA sequence-linked healthcare database globally to better enable improved drug discovery and development.

TD Cowen recently maintained a Buy rating on the stock but lowered the price target to $1,030 from $1,230, based on ongoing legal challenges and preannounced January figures for a key product in the portfolio of Regeneron, EYLEA. The firm significantly lowered its revenue estimates for the Eylea franchise while mentioning increased competition in the market.

Page 4 of 14